Biocardia Inc (BCDA) - Total Assets
Based on the latest financial reports, Biocardia Inc (BCDA) holds total assets worth $6.15 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Biocardia Inc shareholders equity for net asset value and shareholders' equity analysis.
Biocardia Inc - Total Assets Trend (1995–2024)
This chart illustrates how Biocardia Inc's total assets have evolved over time, based on quarterly financial data.
Biocardia Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Biocardia Inc's total assets of $6.15 Million consist of 70.4% current assets and 29.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Biocardia Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BCDA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biocardia Inc's current assets represent 70.4% of total assets in 2024, an increase from 58.2% in 1995.
- Cash Position: Cash and equivalents constituted 63.7% of total assets in 2024, up from 3.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1995.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biocardia Inc Competitors by Total Assets
Key competitors of Biocardia Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Biocardia Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.62 | 1.78 | 5.33 |
| Quick Ratio | 1.62 | 1.78 | 5.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.06 Million | $2.22 Million | $18.41 Million |
Biocardia Inc - Advanced Valuation Insights
This section examines the relationship between Biocardia Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.13 |
| Latest Market Cap to Assets Ratio | 3.16 |
| Asset Growth Rate (YoY) | 24.7% |
| Total Assets | $3.72 Million |
| Market Capitalization | $11.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biocardia Inc's assets at a significant premium (3.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Biocardia Inc's assets grew by 24.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biocardia Inc (1995–2024)
The table below shows the annual total assets of Biocardia Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.72 Million | +24.67% |
| 2023-12-31 | $2.99 Million | -69.50% |
| 2022-12-31 | $9.79 Million | -37.70% |
| 2021-12-31 | $15.72 Million | -32.90% |
| 2020-12-31 | $23.42 Million | +205.08% |
| 2019-12-31 | $7.68 Million | +19.65% |
| 2018-12-31 | $6.42 Million | -52.60% |
| 2017-12-31 | $13.54 Million | -38.69% |
| 2016-12-31 | $22.08 Million | +59.14% |
| 2015-12-31 | $13.88 Million | +2.44% |
| 2014-12-31 | $13.54 Million | +1.63% |
| 2013-12-31 | $13.33 Million | +0.20% |
| 2012-12-31 | $13.30 Million | -3.15% |
| 2011-12-31 | $13.73 Million | +152.70% |
| 2010-12-31 | $5.43 Million | -65.13% |
| 2009-12-31 | $15.59 Million | +35.85% |
| 2008-12-31 | $11.47 Million | +13071.85% |
| 2007-12-31 | $87.11K | -50.20% |
| 2006-12-31 | $174.92K | -80.51% |
| 2005-12-31 | $897.27K | -47.41% |
| 2004-12-31 | $1.71 Million | -35.43% |
| 2003-12-31 | $2.64 Million | -10.78% |
| 2002-12-31 | $2.96 Million | -29.28% |
| 2001-12-31 | $4.19 Million | -43.63% |
| 2000-12-31 | $7.43 Million | +132.15% |
| 1999-12-31 | $3.20 Million | -21.95% |
| 1998-12-31 | $4.10 Million | -12.77% |
| 1997-12-31 | $4.70 Million | 0.00% |
| 1996-12-31 | $4.70 Million | +400.54% |
| 1995-12-31 | $938.99K | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more